DHR vs NBIX
Danaher Corporation vs Neurocrine Biosciences — AI-powered side-by-side comparison
DHR
Danaher Corporation
63
Buy
VS
NBIX
Neurocrine Biosciences
63
Buy
| Metric | DHR | NBIX |
|---|
| AI Score |
63
|
63
|
| Price |
$204.80
|
$163.26
|
| P/E Ratio |
36.24×
|
23.18×
|
| ROE |
6.9%
|
14.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
58.5%
|
98.0%
|
| Debt / Equity |
0.51×
|
0.11×
|
| Dividend Yield |
0.7%
|
0.0%
|
| RSI (14) |
67.2
|
37.5
|
| Beta |
0.823
|
0.386
|
| Expected Upside |
+1.6%
|
—
|
AI Committee View
Current Innellis committee reasoning for DHR versus NBIX.
The committee scores are tied.
DHR and NBIX both score 63/100.
DHR Committee View
80% agreement
5 analysts
The primary driver is market regime is bullish (bull market -- normal position sizing). The main limiting factor is p/e of 35.9 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 35.9 is moderate-to-rich — Value
NBIX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 21.1% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 101.3% YoY — Growth
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.0% signals elevated volatility — Risk